Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GLS | O94925 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | BCL3 | P20749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543795 | 0.78 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL954760 | 0.75 | MAPT (0.44) | ALDH1A1KMT2AMEN1POLBBCL3 | |
| SCHEMBL957518 | 0.75 | RXFP1 (0.44) | KCNH2BCL3 | |
| SCHEMBL8223960 | 0.72 | BCL3 (0.70) | SMN1; SMN2ALDH1A1KMT2AMEN1BCL3 | |
| SCHEMBL3587804 | 0.71 | MEN1 (0.47) | SMN1; SMN2ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL13543794 | 0.71 | MAPT (0.62) | SMN1; SMN2ALDH1A1KMT2ACYP2D6MEN1 | |
| SCHEMBL955297 | 0.71 | DYRK1A (0.54) | CYP2D6BCL3 | |
| SCHEMBL13543797 | 0.70 | BCL3 (0.47) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL1286719 | 0.70 | L3MBTL1 (0.48) | CYP2D6KCNH2BCL3 | |
| SCHEMBL3588253 | 0.69 | MEN1 (0.44) | SMN1; SMN2ALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| WO-2008007123-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | CDK1, CDK2, CDK4 | SMN1; SMN2 3577/4885ALDH1A1 3489/4885KMT2A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.